We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Signet Announces Availability of two Monoclonal Antibodies, L1 and PTEN

Want a FREE PDF version of this product news?

Complete the form below and we will email you a PDF version of "Signet Announces Availability of two Monoclonal Antibodies, L1 and PTEN "

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:

Signet Laboratories, Inc. has announced the availability of two monoclonal antibodies L1 clone 14.10 and PTEN clone 6H2.1

The mouse monoclonal anti-L1 clone 14.10 recognizes the L1 protein (CD171), a transmembrane protein that belongs to the immunoglobulin supergene family.

Data indicate that L1 may be overexpressed in a variety of carcinomas. Studies have implicated L1 as a marker of unfavorable prognosis in a variety of malignancies.

Clone 6H2.1 recognizes PTEN (phosphatase and tensin homolog), a tumor suppressor protein that is encoded by a gene located on chromosome 10. PTEN mutations have been observed in a wide range of cancers.

The addition of L1 and PTEN complements Signet's current product offerings for cancer research. Signet's product portfolio includes markers such as D2- 40, Cyclin D1, Cyclin E, HE4 and Hepsin.